Dale J. Christensen, Ph.D.
Head of Clinical Development
Since the formation of TFF Pharmaceuticals, Dr. Christensen has successfully translated three programs from concept to Phase 1 clinical trials and leads the non-clinical and clinical development activities for TFFP. He is a biotech executive and consultant with over 25 years of R&D experience at the therapeutic interface of chemistry and biology experience managing research and early development across respiratory, inflammation, CNS, anti-infective, and oncology indications.
Dr. Christensen also holds an appointment as Adjunct Associate Professor of Medicine at Duke University Medical Center. He has held senior positions at Spyryx Biosciences, Oncotide, Cognosci, Affinergy Inc., Aryzun Pharmaceuticals, and KaroBio USA (formerly Novalon Pharmaceuticals).
In addition to running research programs for each company, he has also provided oversight of clinical trial design and execution; biomarker development; toxicology study design and execution; and CMC activities for multiple compounds, filing IND/CTA/CTNs, and early-stage trials.
Dr. Christensen has been involved in companies that have raised more than $100M in funding from venture capital groups and $50M in public markets. In addition, he has negotiated strategic partnerships with large pharma and managed external alliances with both large pharma and academic labs.
Dr. Christensen received his B.S. in Chemistry from Utah State University, and a Ph.D. in Organic Chemistry from the University of Utah. He was an NIH Postdoctoral Fellow at Texas A&M University. He has published many papers and is an inventor on numerous patents and patent applications in drug discovery.